Insmed Inc (INSM)vsNeOnc Technologies Holdings, Inc. Common Stock (NTHI)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NTHI
NeOnc Technologies Holdings, Inc. Common Stock
$7.08
-5.98%
HEALTHCARE · Cap: $192.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1010773% more annual revenue ($606.42M vs $59,990). NTHI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NTHI
Avoid14
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NTHI
The strongest argument for NTHI centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NTHI
The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NTHI is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NTHI generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 14/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
NeOnc Technologies Holdings, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
NeOnc Technologies Holdings, Inc. is a biotechnology company focused on the development and commercialization of cutting-edge cancer therapies, primarily through immunotherapy and molecular medicine. With a robust pipeline of innovative product candidates aimed at addressing significant unmet needs in oncology, NeOnc is well-positioned to transform treatment paradigms and improve patient outcomes. The company's strategic partnerships within the biopharmaceutical industry enhance its ability to advance its therapeutic innovations, making it a compelling investment opportunity in the fast-growing cancer therapeutics space.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?